CEL -SCI is expanding the scope of its work for creating a new treatment and vaccination against the current H1N1 virus, and a future mutated form in which the virus has acquired greater morbidity and mortality. It says that the new work would add regions of the hemagglutinin molecule.
CEL-SCI has two on-going research programs directed towards the H1N1 virus, where the first one deals with a future mutated form of virus. The second program is directed at helping sick patients infected with the current form of H1N1. CEL-SCI is expected to give updated communication on that program within the next month.
The company stated that it is focused on creating a treatment/vaccine against such a virus by combining non-changing parts of the H1N1 virus, the Avian Flu virus and the Spanish Flu virus. When a new virus surfaces, this treatment/vaccine is expected to provide an important cornerstone for the fight against the virus.